MRG 201

Drug Profile

MRG 201

Alternative Names: miR-29 replacement; MRG-201

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Yale University
  • Class Antifibrotics; MicroRNAs; Skin disorder therapies
  • Mechanism of Action Collagen inhibitors; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibrosis
  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 11 Sep 2017 Pharmacodynamics data from a preclinical trial in Pulmonnary fibrosis presented at the European Respiratory Society International Congress (ERS-2017)
  • 01 Sep 2017 Preclinical trials in Pulmonary fibrosis in USA (Inhalation) before September 2017
  • 11 Aug 2017 miRagen Therapeutics plans a phase IIa trial for Fibrosis in patients with a predisposition for keloid formation in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top